Uncategorized - December 23, 2014
Researchers Study Link Between Pandemrix, Narcolepsy
A research team from Finland thinks it knows why about 800 people out of the more than 30 million who received GlaxoSmithKline’s Pandemrix developed narcolepsy. Comparing Pandemrix with Arepanrix, a vaccine used in Canada with the same adjuvant, the researchers found that Pandemrix had more of one structurally altered viral nucleoprotein–a disparity lead researcher Outi […]
Drug Development Pharma - July 2, 2014
Pelago Bioscience enters agreement with GSK
Pelago Bioscience AB has entered a method licensing agreement with GlaxoSmithKline. The agreement regards the use of the Cellular Thermal Shift Assay for determination and quantification of drug–target interactions. Under the agreement, Pelago Bioscience grants GSK a license to the CETSA method for use in research & development. Pelago Bioscience was spun out from the […]
Acquisition - April 22, 2014
Novartis buys GSK oncology unit
GlaxoSmithKline has announced a 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses. The two companies will create a new consumer healthcare business with 2013 pro forma revenues of £6.5 billion. GSK will have majority control with an equity interest of 63.5%. GSK will also acquire Novartis’ global Vaccines business (excluding […]
In a new job - April 2, 2014
GSK Sweden gets new CEO
Niclas Karlsson will be the new CEO for GlaxoSmithKline in Sweden.
Collaboration - February 12, 2014
New European program targets novel antibiotics
More than 30 European universities and companies are joining forces in a 6 year programme funded by the Innovative Medicines Initiative (IMI) to develop novel antibiotics. The initiative is led by GlaxoSmithKline and Uppsala University. The novel antibiotics are being developed against Gram-negative pathogens in a project called ENABLE (European Gram Negative Antibacterial Engine). The ENABLE […]
